If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
7-Dehydrocholesterol (7-DHC) is a zoosterol that functions in the serum as a cholesterol precursor, and is photochemically converted to vitamin D3 in the skin, therefore functioning as provitamin-D3. The presence of this compound in human skin enables humans to manufacture vitamin D3 (cholecalciferol). Upon exposure to ultraviolet UV-B rays in the sun light, 7-DHC is converted into vitamin D3 via previtamin D3 as an intermediate isomer. It is also found in the milk of several mammalian species. Lanolin, a waxy substance that is naturally secreted by wool-bearing mammals, contains 7-DHC which is converted into vitamin D by sunlight and then ingested during grooming as a nutrient. In insects 7-dehydrocholesterol is a precursor for the hormone ecdysone, required for reaching adulthood. 7-DHC was discovered by Nobel-laureate organic chemist Adolf Windaus.
7-Fluorotryptamine (7-FT) is a serotonin receptor modulator and weak GPRC5A agonist of the tryptamine family. It is the 7-fluoro derivative of tryptamine. The drug is a low-potency agonist of the orphan receptor GPRC5A, with an EC50Tooltip half-maximal effective concentration of 7,200 nM. In addition to its GPRC5A agonism, 7-fluorotryptamine interacts with other receptors, such as the serotonin 5-HT4 receptor. Derivatives of 7-fluorotryptamine have been described. 7-Fluorotryptamine was first described in the scientific literature by 1979. Its GPRC5A agonism was first described in 2023. Substituted tryptamine 7-Chlorotryptamine 7-Methyltryptamine 7-Hydroxytryptamine 7-F-5-MeO-MET 7-Chloro-AMT 7-Fluorotryptamine - Isomer Design
The 6d orbitals are destabilized by relativistic effects and spin–orbit interactions near the end of the fourth transition metal series, thus making the high oxidation state roentgenium(V) more stable than its lighter homologue gold(V) (known only in gold pentafluoride, Au2F10) as the 6d electrons participate in bonding to a greater extent. The spin-orbit interactions stabilize molecular roentgenium compounds with more bonding 6d electrons; for example, RgF−6 is expected to be more stable than RgF−4, which is expected to be more stable than RgF−2. The stability of RgF−6 is homologous to that of AuF−6; the silver analogue AgF−6 is unknown and is expected to be only marginally stable to decomposition to AgF−4 and F2. Moreover, Rg2F10 is expected to be stable to decomposition, exactly analogous to the Au2F10, whereas Ag2F10 should be unstable to decomposition to Ag2F6 and F2. Gold heptafluoride, AuF7, is known as a gold(V) difluorine complex AuF5·F2, which is lower in energy than a true gold(VII) heptafluoride would be; RgF7 is instead calculated to be more stable as a true roentgenium(VII) heptafluoride, although it would be somewhat unstable, its decomposition to Rg2F10 and F2 releasing a small amount of energy at room temperature. Roentgenium(I) is expected to be difficult to obtain. Gold readily forms the cyanide complex Au(CN)−2, which is used in its extraction from ore through the process of gold cyanidation; roentgenium is expected to follow suit and form Rg(CN)−2.
Sources: en.wikipedia.org
=== Human === A nomenclature system has been devised for the olfactory receptor family and is the basis for the official Human Genome Project (HUGO) symbols for the genes that encode these receptors. The names of individual olfactory receptor family members are in the format "ORnXm" where:
== June 2012 reconstitution == On 29 June 2012, the Ministry was reconstituted. This followed the retirement of Liz Constable (Education), the removal of Rob Johnson (Police; Road Safety) and the earlier resignation on 12 June of Christian Porter (Treasurer; Attorney General), whose duties had been temporarily split between Premier Colin Barnett and senior minister Norman Moore. Three new ministers were appointed from amongst the parliamentary secretary ranks, and three new secretaries were appointed to replace them. The list below is ordered by decreasing seniority within the Cabinet, as indicated by the Government Gazette and the Hansard index. Blue entries indicate members of the Liberal Party, while green entries indicate members of the National Party.
Probucol was originally designed as an antioxidant polymer stabilizer for rubber tires. It was later found to reduce LDL-C levels independently of the LDL receptor and became a prescription drug. Its approval predated statins by a decade.
Sources: en.wikipedia.org
Dyson joined the faculty at Cornell as a physics professor in 1951, though he still had no doctorate. In December 1952, Oppenheimer, the director of the Institute for Advanced Study in Princeton, New Jersey, offered Dyson a lifetime appointment at the institute, "for proving me wrong", in Oppenheimer's words. Dyson remained at the Institute until the end of his career. In 1957 he became a US citizen. From 1957 to 1961 Dyson worked on Project Orion, which proposed the possibility of space-flight using nuclear pulse propulsion. A prototype was demonstrated using conventional explosives, but the 1963 Partial Test Ban Treaty, in which Dyson was involved and which he supported, permitted only underground nuclear weapons testing, and the project was abandoned in 1965. In 1958 Dyson was a member of the design team under Edward Teller for TRIGA, a small, inherently safe nuclear reactor used throughout the world in hospitals and universities for the production of medical isotopes. In 1966, independently of Elliott H. Lieb and Walter Thirring, Dyson and Andrew Lenard published a paper proving that the Pauli exclusion principle plays the main role in the stability of matter. Hence it is not the electromagnetic repulsion between outer-shell orbital electrons that prevents two stacked wood blocks from coalescing into a single piece, but the exclusion principle applied to electrons and protons that generates the classical macroscopic normal force. In condensed matter physics, Dyson also analysed the phase transition of the Ising model in one dimension and spin waves.
== Ester terminology == IUPAC states normatively that carbamate "esters are often called urethanes or urethans, a usage that is strictly correct only for the ethyl esters." However, as a descriptive matter, the IUPAC recognizes that "An alternative term for the compounds R2NC(=O)OR' (R' not = H), esters of carbamic acids, R2NC(=O)OH, in strict use limited to the ethyl esters, but widely used in the general sense".
== Function == This gene encodes a protein that is a transmembrane receptor for growth hormone. Binding of growth hormone to the receptor leads to reorientation of a pre-assembled receptor dimer dimerization (the receptor may however also exist as monomers on the cell surface ) and the activation of an intra- and intercellular signal transduction pathway leading to growth. A common alternate allele of this gene, called GHRd3, lacks exon three and has been well characterized. Mutations in this gene have been associated with Laron syndrome, also known as the growth hormone insensitivity syndrome (GHIS), a disorder characterized by short stature (proportional dwarfism). Other splice variants, including one encoding a soluble form of the protein (GHRtr), have been observed but have not been thoroughly characterized. Laron mice (that is mice genetically engineered to carry defective Ghr), have a dramatic reduction in body mass (only reaching 50% of the weight of normal siblings), and also show a ~40% increase in lifespan.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.